Transdermal Diagnostics Ltd is thrilled to announce a significant funding milestone, having raised 799,935 to propel its revolutionary mission forward. As a pioneering MedTech venture spun out of the University of Bath, Transdermal Diagnostics is redefining patient care through the development of cutting-edge bio-wearable technology. Our journey is driven by a deep commitment to enhancing the prevention, diagnosis, and management of chronic conditions by enabling non-invasive, continuous monitoring of key health biomarkers. This latest injection of funds will be dedicated to the development of the world’s first 100% needle-free and pain-free continuous glucose monitoring (CGM) system.
This groundbreaking device is set to transform the lives of individuals managing diabetes, pre-diabetes, and obesity by providing real-time, personalized biological insights. With this tool, patients will be empowered to make informed decisions about their health, ultimately improving their quality of life and reducing the burden of chronic disease management. The raised capital will accelerate research and development efforts, refine our bio-wearable technology, and support critical clinical trials to ensure our solution meets the highest standards of accuracy and user comfort.
By bridging advanced biomedical engineering with user-centric design, Transdermal Diagnostics is at the forefront of a paradigm shift in healthcare. We are excited to harness this funding to fuel innovation, expand our operational capabilities, and ultimately make a tangible impact on patient outcomes across a spectrum of chronic health conditions. This is a proud moment for our team, partners, and the broader healthcare community, as we continue our commitment to revolutionize health diagnostics and empower individuals to take control of their well-being.
